Universitą degli studi di Pavia
Contenuto della pagina
Orena's curriculum
Curriculum
Personal Information
Name
Beatrice Silvia Orena
Adress Corte Belgioioso 6, 20085, Locate di Triulzi (MI)
Telephone +39 338 4079809
E-mail beatricesilvia.orena01@universitadipavia.it
Nazionality Italian
Date of birth 27/03/1990
Education and Training
01/11/2014 – Present
PhD Program in “Genetics, Molecular and Cellular Biology”, University of Pavia, XXX cycle (2014/2017). Supervisor: Prof. Maria Rosalia Pasca.
December 2014
Italian Biologist Board Certification
10/10/2012 – 25/06/2014
Master Degree in "Experimental and Applied Biology" (Curriculum: “Human Biology and Biomedical Sciences), University of Pavia, Italy.”. Thesis: “Caratterizzazione del meccanismo di inattivazione di un nuovo farmaco antitubercolare”. Supervisor: Prof. Maria Rosalia Pasca. 110/110 cum laude.
13/10/2009 – 25/10/2012 Bachelor Degree in "Biological Sciences", University of Pavia, Italy. Thesis: “Mycobacterium tuberculosis: un nuovo possibile farmaco nell'era della multiresistenza”. Supervisor: Prof. Maria Rosalia Pasca. 105/110.
Diploma di scuola superiore, Liceo Scientifico Biologico Blaise Pascal, Ovada (AL), Italia. Votazione: 100/100 con lode.
Work Experience
01/11/14 - Present PhD Program in “Genetics, Molecular and Cellular Biology”, University of Pavia, XXX cycle (2014/2017). Supervisor: Prof. Maria Rosalia Pasca.
30/11/2015 – 16/12/2015 Tutoring activity “Integrated Laboratory of Experimental Biology (Microbiology), University of Pavia, Italy.
17/07/2013 – 16/07/2014 Tutoring activity "Assistance to students in orientation activities", University of Pavia, Italy.
26/10/2012 – 25/06/2014 Internship for Experimental Thesis for the Master Degree "Human Biology and Biomedic Sciences", at Molecular Microbiology Laboratory, Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Italy. Supervisor: Prof. Maria Rosalia Pasca.
15/04/2012 – 25/10/2012 Internship for Experimental Thesis for the Bachelor Degree "Biological Sciences", at Molecular Microbiology Laboratory, Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Italy. Supervisor: Prof. Maria Rosalia Pasca.
Technical skills and competences
Authorization to work in Biosafety Level 3 (BLS3) laboratory with M. tuberculosis and M. avium complex.
Microbiological techniques
Liquid and solid media preparation; sterilization techniques; bacterial cultures and stricks (E. coli, M. smegmatis, M. tuberculosis); bacterial transformation by electroporation with E. coli, M. smegmatis, and M. tuberculosis; minimal inhibitory concentration (MIC) determination in E. coli, M. smegmatis and M. tuberculosis.
Molecular biology tecniques
Digestion of DNA by restriction enzymes; PCR amplification; Real-time PCR; plasmid DNA extraction and purification; gene cloning; genomic DNA extraction and purification from M. tuberculosis; RNA extraction from M. tuberculosis; gene inactivation in M. tuberculosis by recombineering method; DNA extraction from stool and mucus samples.
Biochemistry tecniques
Heterologous expression and purification of recombinant proteins in E.coli; SDS-PAGE; use of spectrophotometer.
Bioinformatic tecniques
Use of websites e software that help the annotation and the exploration of genomic data (ClustalW, Blastn, Blastp); analysis of Sanger sequencing data.
Informatic Tecniques
Microsoft Office TM software (Word TM, Excel TM, PowerPoint TM).
Languages
• Italian: Mother tongue
• English: B1 (Understanding, speaking, writing)
Awards
June 2016: 2° Award for the obtained results from the “Scientific Advisor Commitee”.12th Consortium Meeting, More Medicines for Tuberculosis (MM4TB), Hotel Devin, Bratislava.
Publications
Papers
1. Menendez C, Mori G, Maillot M, Fabing I, Carayon C, Orena BS, Pasca MR, Voitenko Z, Lherbet C, Baltas M (2015). Synthesis and evaluation of 2-triazolethanol and a,b-diketotriazoles as Antitubercular Agents. French-Ukrainian Journal of Chemistry. 3: 82-96.
2. Laborde J, Deraeve C, Lecoq L, Sournia-Saquet A, Stigliani J-L, Orena BS, Mori G, Pratviel G, Bernardes-Génisson V (2016). Synthesis, oxidation potential and anti–mycobacterial activity of isoniazid and analogues: insights into the molecular isoniazid activation mechanism. Chemistry Select. 1: 172–179.
3. Matviiuk T, Madacki J, Mori G, Orena BS, Menendez C, Kysil A, André-Barrčs C, Rodriguez F, Kordulįkovį J, Mallet-Ladeira S, Voitenko Z, Pasca MR, Lherbet C,Baltas M (2016). Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis. Eur J Med Chem. 123:462-75.
4. Veau D, Krykun S, Mori G, Orena BS, Pasca MR, Frongia C, Lobjois V, Chassaing S, Lherbet C, Baltas M (2016). Triazolophthalazines: Easily Accessible Compounds with Potent Antitubercular Activity. ChemMedChem. 11:1078-89.
5. Chiarelli LR, Mori G, Esposito M, Orena BS, Pasca MR (2016). New and Old Hot Drug Targets in Tuberculosis. Curr Med Chem. In press.
Oral Communications
20-23/09/16
Orena BS, Chiarelli LR, Esposito M, Mori G, Buttari N, Degiacomi G, Gosetti F, Manfredi M, Ekins S, Mikušovį K, Bellinzoni M, Manganelli R, Marengo E, Ballell-Pages L, Riccardi G, Pasca MR. “Multitargeting antitubercular compounds: a new preciuos tool in multidrug resistance age”. FISV 2016 – XIV Congress, University Sapienza of Rome, Rome.
27-28/06/16
Orena BS, Chiarelli LR, Esposito M, Mori G, Pasca MR, Riccardi G. “Last update from Pavias”. 12th Consortium Meeting, More Medicines for Tuberculosis (MM4TB), Hotel Devin, Bratislava.
11-12/01/2016
Orena BS, Chiarelli LR, Esposito M, Mori G, Pasca MR, Riccardi G. “PyrG and Rv0579: two promising drug targets”. 11th Consortium Meeting, More Medicines for Tuberculosis (MM4TB) Hotel Moderno, Pavia.
Posters to national and international meetings
17-19/10/16
Mori G, Orena BS, Armanini F, Segata N, DeMaio G, Rengucci C, Barbieri G, Albertini A, Ranzani GN, Calistri C, Pasca MR. “Study of the intestinal microbiome in the progression of sporadic colorectal adenoma-carcinoma sequence”. 4th World Congress on Targeting Microbiota, Institut Pasteur, Paris.
19-23/09/16
Chiarelli LR, Esposito M, Orena BS, Mori G, Buttari N, Degiacomi G, Gosetti F, Manfredi M, Ekins S, Mikušovį K, Bellinzoni M, Manganelli R, Marengo E, Ballell-Pages L, Riccardi G, Pasca MR. “Mycobacterium tuberculosis CTP synthetase and pantothenate kinase: two promising targets for the development of multitargeting drugs”. EMBO Conference Tuberculosis 2016, Institut Pasteur, Paris.
(Selected for oral presentation)
12-14/05/16
Esposito M, Chiarelli LR, Mori G, Orena BS, Pasca MR, Riccardi G. “Mycobacterium tuberculosis CTP synthetase and pantothenate kinase: two promising targets for the development of multitargeting drugs”. Cortona Procarioti 2016.
(Selected for oral presentation).
23-26/09/2015
Mori G*, Orena BS*, Chiarelli LR, Esposito M, Anatriello M, Makarov M, Riccardi G, Pasca MR. “Characterization of the mechanism of resistance to the new antitubercular nitro-thienopyrimidine TP053”. “Microbiology 2015”, 31st Meeting of Societą Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM), Palazzo dei Congressi, Ravenna.
* (Contributed equally).
23-26/09/2015
Chiarelli LR, Esposito M, Mori G, Orena BS, Makarov V, Bellinzoni M, Degiacomi G, Boldrin F, Marino LB, Manganelli R, Fondi M, Fani R, Mikusovą K, S. de Cavalero LP, Cole ST, Riccardi G, Pasca MR. “Mechanism of action of the new antitubercular thiophenecarboxamide derivatives: a multidisciplinary approach”. “Microbiology 2015”, 31st Meeting of Societą Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM), Palazzo dei Congressi, Ravenna.
(Selected for oral presentation).
Research Project
Research project: “Identification of the mechanisms of action and resistance of new antitubercular drugs”
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and it is still one of the major global public health problems. Because of the spreading of M. tuberculosis multidrug-resistant strains (MDR, XDR, and TDR) there is an urgent need to develop new antitubercular drugs.
Within this context, our laboratory, which is part of the project “More Medicines for Tuberculosis” (MM4TB), funded by the European Commission (EC-VII Framework Program), has the task to identify the mechanism of action and resistance of new antitubercular drugs.
Personal Information
Name
Beatrice Silvia Orena
Adress Corte Belgioioso 6, 20085, Locate di Triulzi (MI)
Telephone +39 338 4079809
E-mail beatricesilvia.orena01@universitadipavia.it
Nazionality Italian
Date of birth 27/03/1990
Education and Training
01/11/2014 – Present
PhD Program in “Genetics, Molecular and Cellular Biology”, University of Pavia, XXX cycle (2014/2017). Supervisor: Prof. Maria Rosalia Pasca.
December 2014
Italian Biologist Board Certification
10/10/2012 – 25/06/2014
Master Degree in "Experimental and Applied Biology" (Curriculum: “Human Biology and Biomedical Sciences), University of Pavia, Italy.”. Thesis: “Caratterizzazione del meccanismo di inattivazione di un nuovo farmaco antitubercolare”. Supervisor: Prof. Maria Rosalia Pasca. 110/110 cum laude.
13/10/2009 – 25/10/2012 Bachelor Degree in "Biological Sciences", University of Pavia, Italy. Thesis: “Mycobacterium tuberculosis: un nuovo possibile farmaco nell'era della multiresistenza”. Supervisor: Prof. Maria Rosalia Pasca. 105/110.
Diploma di scuola superiore, Liceo Scientifico Biologico Blaise Pascal, Ovada (AL), Italia. Votazione: 100/100 con lode.
Work Experience
01/11/14 - Present PhD Program in “Genetics, Molecular and Cellular Biology”, University of Pavia, XXX cycle (2014/2017). Supervisor: Prof. Maria Rosalia Pasca.
30/11/2015 – 16/12/2015 Tutoring activity “Integrated Laboratory of Experimental Biology (Microbiology), University of Pavia, Italy.
17/07/2013 – 16/07/2014 Tutoring activity "Assistance to students in orientation activities", University of Pavia, Italy.
26/10/2012 – 25/06/2014 Internship for Experimental Thesis for the Master Degree "Human Biology and Biomedic Sciences", at Molecular Microbiology Laboratory, Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Italy. Supervisor: Prof. Maria Rosalia Pasca.
15/04/2012 – 25/10/2012 Internship for Experimental Thesis for the Bachelor Degree "Biological Sciences", at Molecular Microbiology Laboratory, Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Italy. Supervisor: Prof. Maria Rosalia Pasca.
Technical skills and competences
Authorization to work in Biosafety Level 3 (BLS3) laboratory with M. tuberculosis and M. avium complex.
Microbiological techniques
Liquid and solid media preparation; sterilization techniques; bacterial cultures and stricks (E. coli, M. smegmatis, M. tuberculosis); bacterial transformation by electroporation with E. coli, M. smegmatis, and M. tuberculosis; minimal inhibitory concentration (MIC) determination in E. coli, M. smegmatis and M. tuberculosis.
Molecular biology tecniques
Digestion of DNA by restriction enzymes; PCR amplification; Real-time PCR; plasmid DNA extraction and purification; gene cloning; genomic DNA extraction and purification from M. tuberculosis; RNA extraction from M. tuberculosis; gene inactivation in M. tuberculosis by recombineering method; DNA extraction from stool and mucus samples.
Biochemistry tecniques
Heterologous expression and purification of recombinant proteins in E.coli; SDS-PAGE; use of spectrophotometer.
Bioinformatic tecniques
Use of websites e software that help the annotation and the exploration of genomic data (ClustalW, Blastn, Blastp); analysis of Sanger sequencing data.
Informatic Tecniques
Microsoft Office TM software (Word TM, Excel TM, PowerPoint TM).
Languages
• Italian: Mother tongue
• English: B1 (Understanding, speaking, writing)
Awards
June 2016: 2° Award for the obtained results from the “Scientific Advisor Commitee”.12th Consortium Meeting, More Medicines for Tuberculosis (MM4TB), Hotel Devin, Bratislava.
Publications
Papers
1. Menendez C, Mori G, Maillot M, Fabing I, Carayon C, Orena BS, Pasca MR, Voitenko Z, Lherbet C, Baltas M (2015). Synthesis and evaluation of 2-triazolethanol and a,b-diketotriazoles as Antitubercular Agents. French-Ukrainian Journal of Chemistry. 3: 82-96.
2. Laborde J, Deraeve C, Lecoq L, Sournia-Saquet A, Stigliani J-L, Orena BS, Mori G, Pratviel G, Bernardes-Génisson V (2016). Synthesis, oxidation potential and anti–mycobacterial activity of isoniazid and analogues: insights into the molecular isoniazid activation mechanism. Chemistry Select. 1: 172–179.
3. Matviiuk T, Madacki J, Mori G, Orena BS, Menendez C, Kysil A, André-Barrčs C, Rodriguez F, Kordulįkovį J, Mallet-Ladeira S, Voitenko Z, Pasca MR, Lherbet C,Baltas M (2016). Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis. Eur J Med Chem. 123:462-75.
4. Veau D, Krykun S, Mori G, Orena BS, Pasca MR, Frongia C, Lobjois V, Chassaing S, Lherbet C, Baltas M (2016). Triazolophthalazines: Easily Accessible Compounds with Potent Antitubercular Activity. ChemMedChem. 11:1078-89.
5. Chiarelli LR, Mori G, Esposito M, Orena BS, Pasca MR (2016). New and Old Hot Drug Targets in Tuberculosis. Curr Med Chem. In press.
Oral Communications
20-23/09/16
Orena BS, Chiarelli LR, Esposito M, Mori G, Buttari N, Degiacomi G, Gosetti F, Manfredi M, Ekins S, Mikušovį K, Bellinzoni M, Manganelli R, Marengo E, Ballell-Pages L, Riccardi G, Pasca MR. “Multitargeting antitubercular compounds: a new preciuos tool in multidrug resistance age”. FISV 2016 – XIV Congress, University Sapienza of Rome, Rome.
27-28/06/16
Orena BS, Chiarelli LR, Esposito M, Mori G, Pasca MR, Riccardi G. “Last update from Pavias”. 12th Consortium Meeting, More Medicines for Tuberculosis (MM4TB), Hotel Devin, Bratislava.
11-12/01/2016
Orena BS, Chiarelli LR, Esposito M, Mori G, Pasca MR, Riccardi G. “PyrG and Rv0579: two promising drug targets”. 11th Consortium Meeting, More Medicines for Tuberculosis (MM4TB) Hotel Moderno, Pavia.
Posters to national and international meetings
17-19/10/16
Mori G, Orena BS, Armanini F, Segata N, DeMaio G, Rengucci C, Barbieri G, Albertini A, Ranzani GN, Calistri C, Pasca MR. “Study of the intestinal microbiome in the progression of sporadic colorectal adenoma-carcinoma sequence”. 4th World Congress on Targeting Microbiota, Institut Pasteur, Paris.
19-23/09/16
Chiarelli LR, Esposito M, Orena BS, Mori G, Buttari N, Degiacomi G, Gosetti F, Manfredi M, Ekins S, Mikušovį K, Bellinzoni M, Manganelli R, Marengo E, Ballell-Pages L, Riccardi G, Pasca MR. “Mycobacterium tuberculosis CTP synthetase and pantothenate kinase: two promising targets for the development of multitargeting drugs”. EMBO Conference Tuberculosis 2016, Institut Pasteur, Paris.
(Selected for oral presentation)
12-14/05/16
Esposito M, Chiarelli LR, Mori G, Orena BS, Pasca MR, Riccardi G. “Mycobacterium tuberculosis CTP synthetase and pantothenate kinase: two promising targets for the development of multitargeting drugs”. Cortona Procarioti 2016.
(Selected for oral presentation).
23-26/09/2015
Mori G*, Orena BS*, Chiarelli LR, Esposito M, Anatriello M, Makarov M, Riccardi G, Pasca MR. “Characterization of the mechanism of resistance to the new antitubercular nitro-thienopyrimidine TP053”. “Microbiology 2015”, 31st Meeting of Societą Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM), Palazzo dei Congressi, Ravenna.
* (Contributed equally).
23-26/09/2015
Chiarelli LR, Esposito M, Mori G, Orena BS, Makarov V, Bellinzoni M, Degiacomi G, Boldrin F, Marino LB, Manganelli R, Fondi M, Fani R, Mikusovą K, S. de Cavalero LP, Cole ST, Riccardi G, Pasca MR. “Mechanism of action of the new antitubercular thiophenecarboxamide derivatives: a multidisciplinary approach”. “Microbiology 2015”, 31st Meeting of Societą Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM), Palazzo dei Congressi, Ravenna.
(Selected for oral presentation).
Research Project
Research project: “Identification of the mechanisms of action and resistance of new antitubercular drugs”
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and it is still one of the major global public health problems. Because of the spreading of M. tuberculosis multidrug-resistant strains (MDR, XDR, and TDR) there is an urgent need to develop new antitubercular drugs.
Within this context, our laboratory, which is part of the project “More Medicines for Tuberculosis” (MM4TB), funded by the European Commission (EC-VII Framework Program), has the task to identify the mechanism of action and resistance of new antitubercular drugs.
